Abstract
Use of cardiac biomarkers for care of patients presenting to the emergency department has a rich history beginning in the 1950s. Aspartate aminotransferase, lactate dehydrogenase isoenzymes, creatine kinase and its MB isoenzyme and myoglobin have all been utilized over the years. However a sentinel event occurred in the 1990s with the availability of assays for the myocardial specific biomarkers cardiac troponin T (cTnT) and cardiac troponin I (cTnI). Along with clinical features and the electrocardiogram, cTnI and cTnT measurements are now a cornerstone for early risk stratification, the diagnosis of myocardial infarction and clinical decision-making in the context of suspected acute coronary syndrome patients in the emergency department. Point-of-care measurements of cardiac troponin and other markers have been implemented at many institutions where the central laboratory is unable to provide results in one hour or less from the time of collection. Because cTnT and cTnI are believed to be released only upon myocardial necrosis, there has been substantial effort in identifying markers of myocardial ischemia that do not necessarily have irreversible cell death. Promising markers include ischemia modified albumin, C-reactive protein, myloperoxidase as well as B-type natriuretic peptide and its biologically inactive co-metabolite NT-proBNP. Also, attention has turned to measurement of very low troponin concentrations measured using assays that are able to measure troponin reliably at concentrations 10- to 100-fold lower than the best conventional troponin assays, with the idea of specifically detecting subtle cardiac injury associated with unstable angina. There are a number of clinical confounders for measurements including renal insufficiency, end stage renal disease, blunt chest trauma, pulmonary embolism, chemotherapy and recent cardiac procedures. Interpretation of cardiac marker results in these clinical circumstances can be complicated and the clinical course of the patient relative to temporal increase in biomarkers must be taken into account.
Few tests have the clinical value and impact of cTnT and cTnI, and it is unlikely that these tests will be replaced for the diagnosis of MI in the foreseeable future. For risk stratification and patient management, however, other markers of inflammation, heart dysfunction or the coagulation process may provide complementary information. Some of these novel markers may come from the proteomic, metabolomic and molecular diagnostic studies. However, it is critical to note that the real value of any new or existing markers will hinge on evidence that their utilization can be shown to improve clinical and/or economic outcomes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007;115:e356–75.
Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Circulation. 2007;116:2634–53.
Fleming SM, O'Byrne L, Finn J, Grimes H, Daly KM. False-positive cardiac troponin I in a routine clinical population. Am J Cardiol 2002;89:1212–5.
Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007;115:e352–5.
Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342–9.
Mair J, Jaffe AS, Christenson RH, Wu AHB, Panteghini M, Ordonez J, Apple FS. Quality Specifications for Cardiac Troponin. Clin Chem 2008 (in press).
Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996;335:1333–41.
Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation 1996;93:1651–7.
Morrow DA, Rifai N, Tanasijevic MJ, Wybenga DR, de Lemos JA, Antman EM. Clinical Efficacy of Three Assays for Cardiac Troponin I for Risk Stratification in Acute Coronary Syndromes: A Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. Clin Chem 2000;46:453–460.
Kaul P, Newby LK, Fu Y, Hasselblad V, Mahaffey KW, Christenson RH, et al. Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. J Am Coll Cardiol 2003;41:371–80.
Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38:478–85.
Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al. Ability of minor elevations of troponin I and T to identify patients with unstable angina and non-ST elevation myocardial infarction who benefit from an early invasive strategy: Results from a prospective, randomized trial. JAMA 2001;286:2405–2412.
Morrow DA, Antman EM, Tanasijevic M, Rifai N, de Lemos JA, McCabe CH, et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI 11B substudy. J Am Coll Cardiol 2000;36:1812–7.
Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al. Ability of minor elevations of troponin I and T to identify patients with unstable angina and non-ST elevation myocardial infarction who benefit from an early invasive strategy: Results from a prospective, randomized trial. JAMA 2001;286:2405–2412.
Venge P, Lagerqvist B, Diderholm E, Lindahl B, Wallentin L. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). Am J Cardiol 2002;89:1035–41.
Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction– summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366–74.
Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al. Ability of minor elevations of troponin I and T to identify patients with unstable angina and non-ST elevation myocardial infarction who benefit from an early invasive strategy: Results from a prospective, randomized trial. JAMA 2001;286:2405–2412
Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829–35.
Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol 1997;29:43–8.
Kontos MC, Anderson FP, Hanbury CM, Roberts CS, Miller WG, Jesse RL. Use of the combination of myoglobin and CK-MB mass for the rapid diagnosis of acute myocardial infarction. Am J Emerg Med 1997;15:14–9.
Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos L, DiBattiste P, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST elevation MI: BNP and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264–1272.
Morrow DA, Rifai N, Tanasijevic MJ, Wybenga DR, de Lemos JA, Antman EM. Clinical Efficacy of Three Assays for Cardiac Troponin I for Risk Stratification in Acute Coronary Syndromes: A Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. Clin Chem 2000;46:453–460.
Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51:810–24.
Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000;19:311–5.
Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J. 2006;152:253–62.
Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440–5.
Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595–604.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135–43.
Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417–24.
Pietila K, Hermens WT, Harmoinen A, Baardman T, Pasternack A, Topol EJ, et al. Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase. Am J Cardiol 1997;80:1075–7.
Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000;343:1139–47.
Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998;31:1460–5.
Azzazy HM, Christenson RH. B-type natriuretic peptide: physiologic role and assay characteristics. Heart Fail Rev 2003;8:315–20.
Tateishi J, Masutani M, Ohyanagi M, Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 2000;23:776–80.
de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316–22.
e Lemos JA, Morrow DA. Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? Circulation 2002;106:2868–70.
Omland T, de Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, et al. Prognostic Value of N-terminal Pro-Atrial and Pro-Brain Natriuretic Peptide in Patients with Acute Coronary Syndromes: A TIMI 11B substudy. Am J Cardiol 2002;89:463–465.
Arakawa N, Nakamura M, Aoki H, Hiramori K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 1996;27:1656–61.
Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921–9.
de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014–21.
Stein PD, Hull RD, Patel KC, Olson RE, Ghali WA, Brant R, Biel RK, Bharadia V, Kalra NK. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review Ann Intern Med 2004:20;140:589–602.
Roe MT, Christenson RH, Ohman EM, Bahr R, Fesmire FM, Storrow A et al. A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. Am Heart J 2003;146:993–8.
Lee-Lewandrowski E, Corboy D, Lewandrowski K, Sinclair J, McDermot S, Benzer TI. Implementation of a point-of-care satellite laboratory in the emergency department of an academic medical center. Impact on test turnaround time and patient emergency department length of stay. Arch Pathol Lab Med 2003;127:456–60.
Nichols JH, Christenson RH, Clarke W, Gronowski A, Hammett-Stabler CA, Jacobs E et al. Executive summary. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guideline: evidence-based practice for point-of-care testing. Clin Chim Acta 2007;379:14–28.
McCullough PA, Nowack RM, Foreback C, Tokarski G, Tomianovich MC, Khoury KR, et al. Performance of multiple cardiac biomarkers measured in the emergency department in patients with chronic kidney disease and chest pain. Acad Emerg Med 2002;9:1389–96.
Kidney Disease Outcomes Quality Initiative. Clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005;45 (suppl 3): S1–S154.
Jaffe AS. Chasing troponin. How low can you go if you can see the rise? J Am Coll Cardiol 2006;48:1763–4.
Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, et al. Troponin T levels in patients with acute coronary syndromes, with and without renal dysfunction. N Engl J Med 2002;346:2047–52.
Scirica BM, Morrow DA. Troponins in acute coronary syndromes. Prog Cardiovasc Dis 2004;47:177–88.
Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002;106:941–5. 11.
deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, Christenson R, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003;290:353–9.
Wu AH, Jaffe AS, Apple FS, Jesse RL, Francis GL, Morrow DA et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 2007;53:2086–96.
Jackson L, Stewart A. Best evidence topic report. Use of troponin for the diagnosis of myocardial contusion after blunt chest trauma. Emerg Med J 2005;22:193–5.
La Vecchia L, Ottani F, Favero L, Spadaro GL, Rubboli A, Boanno C, et al. Increased cardiac troponin I on admission predicts in-hospital mortality in acute pulmonary embolism. Heart 2004;90:633–7.
Scridon T, Scridon C, Skali H, Alverez A, Goldhaber SZ, Solomon SD. Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism. Am J Cardiol 2005;96:303–5.
Akkerhuis KM, Alexander JH, Tardiff Be, Boersma E, Harrington RA, Lincoll AM, Simoons ML. Minor myocardial damage and prognosis. Are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002;105:554–6.
Cardinale D, Sandri MGT, Martinoni A, Tricca A, Civelli M, Lamantgia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517–22.
Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civilli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–81.
Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241–51.
Silber S, Albertsson P, Aviles FF, Camici P, Colombo A, Hamm C, et al. for The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J 2005;226:804–47.
McCord J, Nowak RM, McCullough PA, Foreback C, Borzak S, Tokarski G, et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 2001;104:1483–8.
Fesmire FM, Fesmire CE. Improved identification of acute coronary syndromes with second generation cardiac troponin I assay: utility of 2-hour delta cTnI > or = +0.02 ng/mL. J Emerg Med 2002;22:147–52.
Fesmire FM, Christenson RH, Fody EP, Feintuch TA. Delta creatine kinase-MB outperforms myoglobin at two hours during the emergency department identification and exclusion of troponin positive non-ST-segment elevation acute coronary syndromes. Ann Emerg Med 2004;44:12–9.
Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760–3.
Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation, 2003:250–2.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Christenson, R.H. (2009). Cardiac Markers: A Chest Pain Center Focus. In: Cannon, C., Peacock, W. (eds) Short Stay Management of Chest Pain. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-60327-948-2_7
Download citation
DOI: https://doi.org/10.1007/978-1-60327-948-2_7
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-947-5
Online ISBN: 978-1-60327-948-2
eBook Packages: MedicineMedicine (R0)